The Food and Drug Administration (FDA) has raised alarms over counterfeit versions of the diabetes medication Ozempic infiltrating the U.S. supply chain. This critical warning comes as the FDA seized ...

None of this is surprising — especially when at least 500,000 Brits are currently taking Mounjaro and Wegovy via private prescription. For many, the prospect of going cold turkey or forking out up to ...

Viking Therapeutics (NASDAQ: VKTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the latter ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

“Most users tolerate GLP-1 medications like Ozempic without serious oral health issues, but a subset experience notable side ...

Fed Chair Powell's dovish Jackson Hole speech sparks a market rally, while tech dips and earnings drive individual stocks ...

The weight-loss drug Wegovy just got FDA approval to treat a common and serious liver condition known as MASH (Metabolic ...

COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...